Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Regeneron stock dips as court denies Eylea patent stay
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Investing2d
Regeneron stock dips as court denies Eylea patent stay
As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...
Zacks.com on MSN10d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo Finance10d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...